<DOC>
	<DOCNO>NCT01132911</DOCNO>
	<brief_summary>Background : - Vorinostat bortezomib anti-tumor drug approve Food Drug Administration treat different kind myeloma lymphoma adult . The combination two drug try small number adult , formally approve experimental , particularly child . Researchers interested determine safe effective treatment dos vorinostat bortezomib child , learn drug affect tumor growth human development . Objectives : - To determine safe effective dos vorinostat bortezomib treat solid tumor child . - To study effect vorinostat bortezomib blood cell , blood flow , human development . Eligibility : - Children , adolescent , young adult 1 21 year age diagnose solid tumor respond treatment . Design : - Eligible participant screen physical examination , blood tumor sample , image study . - Participants 21-day treatment cycle vorinostat bortezomib . Vorinostat give either tablet liquid dos day 1 5 8 12 cycle . Bortezomib give intravenous injection day 1 , 4 , 8 , 11 cycle . Participants keep drug administration diary record information side effect problem treatment . - Participants may continue receive vorinostat bortezomib 2 year unless serious side effect develop tumor respond treatment . - Additional blood sample take regular interval first 3 day first bortezomib dose first 2 day first vorinostat dose first treatment cycle .</brief_summary>
	<brief_title>A Phase I Study Vorinostat Bortezomib Children With Refractory Recurrent Solid Tumors , Including CNS Tumors Lymphomas</brief_title>
	<detailed_description>Background : -The combination vorinostat bortezomib show synergistic vitro variety malignancy , include hepatoma , multiple myeloma , leukemia , lymphoma , gastrointestinal cancer . Currently several phase 2 adult study underway evaluate combination therapy . Objectives : - To determine maximum tolerate dose ( MTD ) and/or recommend Phase 2 dose combination oral vorinostat administer day 1-5 8-12 bortezomib administer intravenously day 1 , 4 , 8 , 11 , every 21 day child refractory recurrent solid tumor . - To define describe toxicity vorinostat combination bortezomib administer schedule . - To characterize pharmacokinetics vorinostat bortezomib combination child refractory recurrent solid tumor . - Secondary objective include preliminary definition antitumor activity agent administer together ; assessment biologic activity bortezomib measure NF-kappaB activity peripheral blood mononuclear cell ( PBMC ) measure endoplasmic reticulum stress response use GRP78 molecular chaperone marker PBMC . Eligibility : - Patients great than12 month le equal 21 year age diagnosis histologic verification ( except patient instrinsic brain stem tumor , optic pathway glioma pineal tumor ) measureable evaluable relapse refractory solid tumor include CNS tumor lymphomas eligible . Current disease state must one know curative therapy , therapy proven prolong survival . - Performance score : Karnofsky great equal 60 % patient great 16 year age ; Lansky great equal 60 patient less equal 16 year age . - Must fully recover acute toxic effect prior therapy complete within specify prior time frame . Have adequate organ function determine laboratory evaluation . Design : - This phase I study vorinostat administer orally daily day 1-5 day 8-12 combination bortezomib administer intravenously day 1 , 4 , 8 , 11 21 day cycle . Disease evaluation perform cycle 1 every 2 cycle thereafter . - Therapy may continue 2 year absence progressive disease unacceptable toxicity . - Optional participation correlative biology study pharmacokinetic study offer .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Eligibility Criteria : Patients older than12 month le equal 21 year age diagnosis histologic verification ( except patient instrinsic brain stem tumor , optic pathway glioma pineal tumor ) measureable evaluable relapse refractory solid tumor include CNS tumor lymphomas eligible . Current disease state must one know curative therapy , therapy proven prolong survival . Performance score : Karnofsky great equal 60 % patient great 16 year age ; Lansky great equal 60 patient less equal 16 year age . Must fully recover acute toxic effect prior therapy complete within specify prior time frame . Have adequate organ function determine laboratory evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 13, 2011</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pediatric Cancer</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Wilms Tumor</keyword>
	<keyword>Neuroblastoma</keyword>
</DOC>